



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

28 April 2016
EMA/CHMP/37597/2016
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

HyQvia

human normal immunoglobulin

On 28 April 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product HyQvia. The marketing authorisation holder for this medicinal product is Baxalta Innovations GmbH.

The CHMP adopted an extension to the existing indication as follows²:

"Replacement therapy in adults, **children and adolescents (0-18 years)** (~~≥ 18 years~~) in:

- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated.
- Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.
- Hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (HSCT)."

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² **New text in bold, removed text as strikethrough**

